FDA
-
-
-
-
-
-
-
Greenwich LifeSciences reports Q1 cash balance of $10.5 million
-
-
-
-
-
-
-
Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01
-
-
-
-
-
-
-
Greenwich LifeSciences (GLSI) Provides Update on Commercial Manufacturing
-
-
-
-
-
-
-
Greenwich LifeSciences (GLSI) Announces Removal of Clinical Hold from GLSI-100 Program
-
-
-
-
-
-
-
Greenwich LifeSciences Announces Update of GP2 Phase III Clinical Trial Design at the 2021 AACR Annual Meeting
-
-
-
-
-
-
-
Pre-Open Stock Movers 12/18: (MREO) (DMTK) (BEAT) Higher; (MESO) (SCHL) (GLSI) Lower (more...)
-
-
-
-
-
-
-
Greenwich LifeSciences Announces Second Publication and Second Poster Presentation of Phase III Clinical Trial of Potential Breakthrough Technology for Recurring Breast Cancer
-
325,892 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

